about
P3320
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine usersTwo subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology.Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic PatientsDecreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode SchizophreniaStructural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia.Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia PatientsEffects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication.P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatmentBrain connectivity studies in schizophrenia: unravelling the effects of antipsychotics.Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trialWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Is an Early Age at Illness Onset in Schizophrenia Associated With Increased Genetic Susceptibility? Analysis of Data From the Nationwide Danish Twin Register.Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia[Patients with first-episode psychosis should not be scanned routinely].Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocolWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genesGlucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.The promise of biological markers for treatment response in first-episode psychosis: a systematic review.Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychoticsCommon variants at VRK2 and TCF4 conferring risk of schizophrenia.Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness.Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockadeFrontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers.Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.Serotonin 2A receptor antagonists for treatment of schizophrenia.Treatment options for residual insomnia in schizophreniaWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactatioImprovement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia.Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment.Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.The effect of acute exogenous melatonin on P50 suppression in healthy male volunteers stratified for low and high gating levels.Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment
P50
Q24186909-CD11DE9C-192F-4610-8336-3C0DD215D888Q29364373-6D973CFE-AC6D-4070-8E43-FD613D5F269EQ29364500-1F230D70-F1E2-4698-94F2-A84767D2F869Q29364524-4553E43A-0224-470C-9D7B-74573544C15EQ29364530-984CD4C8-C6E0-4D10-989B-8EC82FA84E49Q30386772-595AB000-FDDB-425F-B3DD-2120643D9754Q30397569-8DB2521B-25D0-43A3-9AD0-F120F420E38EQ30439307-DA746914-6240-4417-A7EB-BB7649B349DCQ30442472-A1EBA12C-29C6-4D64-917F-51346B7F0BF3Q30596256-65F9F66C-E591-4DCD-9F54-95A3F2462193Q31136492-4E92C55B-23F2-4603-90AF-F50E59A4D2F1Q33223628-569B2362-568D-424C-901C-C596C00D5BDFQ33235110-B8F97743-D3CE-473A-B3F2-CDDF3669738DQ33603715-7ED05DA0-35E8-47A6-A810-ACBCDE93C84BQ33712210-D856DC07-07D4-4AF2-B6C2-E5646EE058CFQ33820354-2078FEEF-15E4-41F1-9DAF-A03FE7827C07Q34041023-AD9ED54E-30C9-4D7C-85E1-C25078BE9B59Q34315836-534B6364-A56A-4556-AD9B-A36F5E234219Q34326175-87774B0C-5F35-4D1E-B3B6-0ACD08C454EBQ34379379-C3438FB7-4451-4FBD-B804-F29E6399AA24Q34640811-1608174B-A7CB-4719-A67F-E06557767957Q35369988-E01F9F7E-AEBF-483C-B607-D23A68754B4EQ35370011-39A35ADF-C2D3-4F6A-9FA0-DD65A2F43365Q35370032-1E25FBAE-E187-4678-809D-960D89CF56B0Q35816788-90B35ED0-3CAE-480C-89D5-6CB715B14641Q35950793-84FDBEAF-EA17-4463-85F1-645232134BA9Q36193455-82F75AD4-925F-4A5F-9939-47A9190B4A17Q36609798-EAA71738-F845-44B7-B4C7-C7F0D25AD8C6Q36950595-54EEB921-0A09-4BC2-A902-660B26DD3BE5Q37461052-F67F1D38-DA3E-4896-8A3C-1872D5DCB9FDQ37633458-40F9BACB-CE21-4D3A-AF1C-0D0CD3B848E1Q37899193-4454D19A-77AB-45C8-AC29-BB658ABC698BQ38056176-4BB5D912-83D6-43BD-924F-C4E8087848B8Q38395937-99BA8BB4-8FDA-4B83-B941-A90314C3A180Q38466601-33071F53-5EC1-47A5-B405-89E796B28887Q39029626-38DB42A1-2779-48A0-B503-65E8D69481DCQ39248594-C0789629-4DBB-4416-8A62-BB6250783EFCQ39613560-7A389433-ED1A-48AD-9985-7CE2CA754319Q39652829-9A39DCB0-D20E-43F2-BC81-F54876768819Q40127515-D42B6E51-3006-45CA-8307-0BCF0B468172
P50
description
dansk professor
@da
hulumtuese
@sq
psychiater
@nl
researcher
@en
հետազոտող
@hy
name
Birte Yding Glenthøj
@ast
Birte Yding Glenthøj
@da
Birte Yding Glenthøj
@de
Birte Yding Glenthøj
@en
Birte Yding Glenthøj
@es
Birte Yding Glenthøj
@fo
Birte Yding Glenthøj
@fr
Birte Yding Glenthøj
@is
Birte Yding Glenthøj
@kl
Birte Yding Glenthøj
@nb
type
label
Birte Yding Glenthøj
@ast
Birte Yding Glenthøj
@da
Birte Yding Glenthøj
@de
Birte Yding Glenthøj
@en
Birte Yding Glenthøj
@es
Birte Yding Glenthøj
@fo
Birte Yding Glenthøj
@fr
Birte Yding Glenthøj
@is
Birte Yding Glenthøj
@kl
Birte Yding Glenthøj
@nb
altLabel
B Y Glenthøj
@da
B Y Glenthøj
@de
B Y Glenthøj
@en
Birte Glenthoj
@da
Birte Glenthoj
@de
Birte Glenthoj
@en
Birte Glenthøj
@da
Birte Glenthøj
@de
Birte Glenthøj
@en
Birte Y Glenthoj
@da
prefLabel
Birte Yding Glenthøj
@ast
Birte Yding Glenthøj
@da
Birte Yding Glenthøj
@de
Birte Yding Glenthøj
@en
Birte Yding Glenthøj
@es
Birte Yding Glenthøj
@fo
Birte Yding Glenthøj
@fr
Birte Yding Glenthøj
@is
Birte Yding Glenthøj
@kl
Birte Yding Glenthøj
@nb
P106
P19
P21
P31
P569
1951-06-19T00:00:00Z